<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02557737</url>
  </required_header>
  <id_info>
    <org_study_id>CMRPG8B0222</org_study_id>
    <nct_id>NCT02557737</nct_id>
  </id_info>
  <brief_title>Botulinim Toxin Type A Injections by Different Guidance in Stroke Patients With Spasticity on Upper Extremities</brief_title>
  <official_title>Comparison of Surface Landmark, Ultrasonography and Electric Stimulation Guidance for Botulinum Toxin Injections in Stroke Patients With Spasticity on Upper Extremities.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aims of this study were to compare the injection locations of key spastic muscles on
      upper extremity by three different guidance localization methods ( surface anatomy landmark,
      ultrasonography, electric stimulation) and the effectiveness.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Stroke may result in acute or chronic hemiplegia and spasticity in stroke patients.
      Spasticity in upper extremities may interfere with motor voluntary function, activities of
      daily living and cause muscle pain. Botulinum toxin type A (BTX-A) has been shown to relieve
      spasticity and pain in upper extremities of stroke patients. There are no researches to
      compare the efficiency of BTX-A by different injection guidance methods in stroke patients.
      The aims of our study were to compare the injection locations of key spastic muscles on upper
      extremity by three different guidance localization methods ( surface anatomy landmark,
      ultrasonography, electric stimulation) and the effectiveness. The investigators will enroll
      60 hemiplegic stroke patients with upper extremity spasticity more than modified Ashworth
      scale ( MAS) 1+ and duration more than 6 months. Under different guidance methods (surface
      anatomy landmark/ ultrasonography /electric stimulation ), BTX-A will be injected to the key
      spastic muscles on upper extremity. Outcome measures include MAS, motor function ( Brunnstrom
      stage of upper extremity), range of motion , the degree and visual analog scale of pain ,
      pinch and grasp power，Stroke Impact Scale, Barthel index and upper extremity function (Nine
      hole peg test，Action Reaearch Arm Test，Wolf Motor Function test，Chedoke Arm and Han Activity
      Inventory，Fugl-Meyer Assessment Scale，Motor Activity Log). All the assessments will be
      performed before BTX-A injection and followed up at 4 weeks, 8 weeks, 12 weeks and 24 weeks
      after injection. After performing all the assessments, investigators will investigate the
      efficiency of BTX-A by different guidance methods.

      Four of arms:

      ultrasonography direct-guidance: To inject Botulinum toxin type A on the spasticity lower
      extremity for stroke patients by Ultrasonography direct-guidance.

      ultrasonography indirect-guidance: To inject Botulinum toxin type A on the spasticity lower
      extremity for stroke patients by Ultrasonography indirect-guidance.

      electric stimulation guidance: To inject Botulinum toxin type A on the spasticity lower
      extremity for stroke patients by electric stimulation guidance.

      surface anatomy landmark: To inject Botulinum toxin type A on the spasticity lower extremity
      for stroke patients by surface anatomy landmark.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Modified Ashworth Scale</measure>
    <time_frame>Change from Baseline Muscle Tone at 6 months</time_frame>
    <description>patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks after injection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brunnstrome Stage</measure>
    <time_frame>Change from Baseline Condition at 6 months</time_frame>
    <description>patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks after injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Active Range of Motion</measure>
    <time_frame>Change from Baseline Data at 6 months</time_frame>
    <description>patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks after injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4 Point Categorical Pain Intensity Scale</measure>
    <time_frame>Change from Baseline Data at 6 months</time_frame>
    <description>patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks after injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hand-grasp strength Assessment</measure>
    <time_frame>Change from Baseline Data at 6 months</time_frame>
    <description>patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks after injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pinch Strength Assessment</measure>
    <time_frame>Change from Baseline Data at 6 months</time_frame>
    <description>patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks after injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barthel Index</measure>
    <time_frame>Change from Baseline Data at 6 months</time_frame>
    <description>patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks after injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke Impact Scale (SIS)</measure>
    <time_frame>Change from Baseline Data at 6 months</time_frame>
    <description>patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks after injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Action Research Arm Test (ARAT)</measure>
    <time_frame>Change from Baseline Data at 6 months</time_frame>
    <description>patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks after injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wolf Motor Function Test</measure>
    <time_frame>Change from Baseline Data at 6 months</time_frame>
    <description>patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks after injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chedoke Arm and Hand Activity Inventory (CAHAI)</measure>
    <time_frame>Change from Baseline Data at 6 months</time_frame>
    <description>patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks after injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fugl-Meyer Assessment</measure>
    <time_frame>Change from Baseline Data at 6 months</time_frame>
    <description>patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks after injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motor Activity Log Scale</measure>
    <time_frame>Change from Baseline Data at 6 months</time_frame>
    <description>patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks after injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nine Hole Peg Test</measure>
    <time_frame>Change from Baseline Data at 6 months</time_frame>
    <description>patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks after injection</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cerebrovascular Accident</condition>
  <arm_group>
    <arm_group_label>Ultrasonography direct-guidance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Ultrasonography direct-guidance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Electric stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Electric stimulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surface anatomy landmark</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Surface anatomy landmark.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum Toxin Type A</intervention_name>
    <description>To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Ultrasonography direct-guidance, Ultrasonography direct-guidance, Electric stimulation and Surface anatomy landmark.</description>
    <arm_group_label>Ultrasonography direct-guidance</arm_group_label>
    <arm_group_label>Electric stimulation</arm_group_label>
    <arm_group_label>Surface anatomy landmark</arm_group_label>
    <other_name>Botulinum toxin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  first onset.

          -  at least onset before 6 months.

          -  elbow, wrist and fingers are above Modified Ashworth Scale(MAS) 1+.

          -  Mini-Mental State Exam above 24.

          -  can follow all of the follow up and instruction.

          -  patients never accept botox, phenol and alcohol injections before.

        Exclusion Criteria:

          -  contracture deformity on upper extremity.

          -  patients had accepted botox before or had have phenol, alcohol injections and
             operation 6 months ago.

          -  allergy to botox.

          -  have neither infection nor skin disorder on inject site.

          -  now accept aminoglycoside or other medicine treatment which may affect neuromuscular
             transition.

          -  combine other systemic disease of neurological or skelectomuscular system

          -  cognition disorder or aphasia after stroke.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pong Ya-Ping, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Rehabilitation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pong Ya-Ping, MD</last_name>
    <phone>889-7-7317123</phone>
    <phone_ext>6286</phone_ext>
    <email>yaping0707@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pong Ya-ping, MD</last_name>
      <phone>889-7-7317123</phone>
      <phone_ext>6286</phone_ext>
      <email>yaping0707@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Mizrahi EM, Angel RW. Impairment of voluntary movement by spasticity. Ann Neurol. 1979 Jun;5(6):594-5.</citation>
    <PMID>475355</PMID>
  </reference>
  <reference>
    <citation>Gracies JM, Nance P, Elovic E, McGuire J, Simpson DM. Traditional pharmacological treatments for spasticity. Part II: General and regional treatments. Muscle Nerve Suppl. 1997;6:S92-120. Review.</citation>
    <PMID>9826984</PMID>
  </reference>
  <reference>
    <citation>Gracies JM, Elovic E, McGuire J, Simpson DM. Traditional pharmacological treatments for spasticity. Part I: Local treatments. Muscle Nerve Suppl. 1997;6:S61-91. Review.</citation>
    <PMID>9826983</PMID>
  </reference>
  <reference>
    <citation>Difazio M, Jabbari B. A focused review of the use of botulinum toxins for low back pain. Clin J Pain. 2002 Nov-Dec;18(6 Suppl):S155-62. Review.</citation>
    <PMID>12569963</PMID>
  </reference>
  <reference>
    <citation>Jankovic J. Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry. 2004 Jul;75(7):951-7. Review.</citation>
    <PMID>15201348</PMID>
  </reference>
  <reference>
    <citation>Lim EC, Seet RC. Use of botulinum toxin in the neurology clinic. Nat Rev Neurol. 2010 Nov;6(11):624-36. doi: 10.1038/nrneurol.2010.149. Epub 2010 Oct 12. Review.</citation>
    <PMID>21045798</PMID>
  </reference>
  <reference>
    <citation>Brashear A, Gordon MF, Elovic E, Kassicieh VD, Marciniak C, Do M, Lee CH, Jenkins S, Turkel C; Botox Post-Stroke Spasticity Study Group. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med. 2002 Aug 8;347(6):395-400.</citation>
    <PMID>12167681</PMID>
  </reference>
  <reference>
    <citation>Yablon SA, Brashear A, Gordon MF, Elovic EP, Turkel CC, Daggett S, Liu J, Brin MF. Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials. Clin Ther. 2007 Apr;29(4):683-90.</citation>
    <PMID>17617291</PMID>
  </reference>
  <reference>
    <citation>Yablon SA, Agana BT, Ivanhoe CB, Boake C. Botulinum toxin in severe upper extremity spasticity among patients with traumatic brain injury: an open-labeled trial. Neurology. 1996 Oct;47(4):939-44.</citation>
    <PMID>8857723</PMID>
  </reference>
  <reference>
    <citation>Bakheit AM, Thilmann AF, Ward AB, Poewe W, Wissel J, Muller J, Benecke R, Collin C, Muller F, Ward CD, Neumann C. A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke. 2000 Oct;31(10):2402-6.</citation>
    <PMID>11022071</PMID>
  </reference>
  <reference>
    <citation>Francisco GE. Botulinum toxin for post-stroke spastic hypertonia: a review of its efficacy and application in clinical practice. Ann Acad Med Singapore. 2007 Jan;36(1):22-30. Review.</citation>
    <PMID>17285183</PMID>
  </reference>
  <reference>
    <citation>Chin TY, Nattrass GR, Selber P, Graham HK. Accuracy of intramuscular injection of botulinum toxin A in juvenile cerebral palsy: a comparison between manual needle placement and placement guided by electrical stimulation. J Pediatr Orthop. 2005 May-Jun;25(3):286-91.</citation>
    <PMID>15832139</PMID>
  </reference>
  <reference>
    <citation>Molloy FM, Shill HA, Kaelin-Lang A, Karp BI. Accuracy of muscle localization without EMG: implications for treatment of limb dystonia. Neurology. 2002 Mar 12;58(5):805-7.</citation>
    <PMID>11889247</PMID>
  </reference>
  <reference>
    <citation>Lim EC, Ong BK, Seet RC. Botulinum toxin-A injections for spastic toe clawing. Parkinsonism Relat Disord. 2006 Jan;12(1):43-7. Epub 2005 Sep 29.</citation>
    <PMID>16198612</PMID>
  </reference>
  <reference>
    <citation>O'Brien CF. Injection techniques for botulinum toxin using electromyography and electrical stimulation. Muscle Nerve Suppl. 1997;6:S176-80. Review.</citation>
    <PMID>9826989</PMID>
  </reference>
  <reference>
    <citation>Alter KE. High-frequency ultrasound guidance for neurotoxin injections. Phys Med Rehabil Clin N Am. 2010 Aug;21(3):607-30. doi: 10.1016/j.pmr.2010.05.001. Review.</citation>
    <PMID>20797552</PMID>
  </reference>
  <reference>
    <citation>Berweck S, Schroeder AS, Fietzek UM, Heinen F. Sonography-guided injection of botulinum toxin in children with cerebral palsy. Lancet. 2004 Jan 17;363(9404):249-50.</citation>
    <PMID>14738817</PMID>
  </reference>
  <reference>
    <citation>Schroeder AS, Berweck S, Lee SH, Heinen F. Botulinum toxin treatment of children with cerebral palsy - a short review of different injection techniques. Neurotox Res. 2006 Apr;9(2-3):189-96. Review.</citation>
    <PMID>16785117</PMID>
  </reference>
  <reference>
    <citation>Depedibi R, Unlü E, Cevikol A, Akkaya T, Cakci A, Cerekçi R, Köse G, Unlüsoy D. Ultrasound-guided botulinum toxin type A injection to the iliopsoas muscle in the management of children with cerebral palsy. NeuroRehabilitation. 2008;23(3):199-205.</citation>
    <PMID>18560136</PMID>
  </reference>
  <reference>
    <citation>Henzel MK, Munin MC, Niyonkuru C, Skidmore ER, Weber DJ, Zafonte RD. Comparison of surface and ultrasound localization to identify forearm flexor muscles for botulinum toxin injections. PM R. 2010 Jul;2(7):642-6. doi: 10.1016/j.pmrj.2010.05.002.</citation>
    <PMID>20659720</PMID>
  </reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2015</study_first_submitted>
  <study_first_submitted_qc>September 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2015</study_first_posted>
  <last_update_submitted>March 28, 2016</last_update_submitted>
  <last_update_submitted_qc>March 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stroke</keyword>
  <keyword>upper extremity</keyword>
  <keyword>spasticity</keyword>
  <keyword>botulinum toxin</keyword>
  <keyword>ultrasonography</keyword>
  <keyword>electric stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscle Spasticity</mesh_term>
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

